In conclusion, these results provide a deeper understanding of the anticancer properties of δ-TT, demonstrating that it exerts potent antitumor activity in PTEN-null and Akt/HK2-overexpressing PCa cells by targeting their specific metabolic features and that it might serve as a promising therapeutic strategy when given in combination with anti-glycolytic agents. Here, AKT1 is linked to posterior cortical atrophy.